Trametinib for progressive pediatric low-grade gliomas
ConclusionTrametinib appears to be a suitable option for refractory pediatric low-grade glioma and warrants further investigations in case of progression.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Astrocytoma | Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Chemotherapy | Children | Gastroenterology | Genetics | Glioma | Neurology | Pediatrics | Pilocytic Astrocytoma | Radiation Therapy | Skin | Toxicology